CYTK

CYTK

USD

Cytokinetics Incorporated Common Stock

$61.480+1.180 (1.957%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$60.300

最高

$61.480

最低

$60.010

交易量

1.92M

公司基本面

市值

7.5B

行業

生物科技

國家

United States

交易統計

平均交易量

2.29M

交易所

NMS

貨幣

USD

52週範圍

最低 $29.31當前 $61.480最高 $64.13

相關新聞

Analyst Upgrades

B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90

B. Riley Securities analyst Mayank Mamtani reiterates Cytokinetics with a Buy and raises the price target from $80 to $90.

查看更多
B. Riley Securities Reiterates Buy on Cytokinetics, Raises Price Target to $90
PR Newswire

Investors in Cytokinetics, Incorporated Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK

The Gross Law Firm issues the following notice to shareholders of Cytokinetics, Incorporated (NASDAQ: CYTK). Shareholders who purchased shares of...

查看更多
Investors in Cytokinetics, Incorporated Should Contact The Gross Law Firm Before November 17, 2025 to Discuss Your Rights - CYTK
GlobeNewswire

Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE

查看更多
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
PR Newswire

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27,...

查看更多
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
PR Newswire

CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27,...

查看更多
CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
GlobeNewswire

Cytokinetics to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that members of the Company management team will participate in the following investor conferences

PR Newswire

Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...